What is Thymulin?
Thymulin is a hormone produced by thymic epithelial cells. Its peptide component, serum thymic factor or FTS, has nine amino acids: pyroglutamyl-Ala-Lys-Ser-Gln-Gly-Gly-Ser-Asn.[2][1]
Zinc binding gives the complex its described immunoregulatory activity. This distinction matters: a peptide sequence, zinc-bound thymulin and a study of zinc supplementation do not describe the same intervention.[1][3]
The hormone participates in communication between the thymus, immune cells and the endocrine system. It is distinct from Thymalin, a mixed thymus extract, and from modified thymulin-related compounds.[1][44]
What Thymulin is investigated for
Thymulin evidence is grouped by practical use case and intraperitoneal route context. Each use case separates confidence, human evidence, animal or mechanistic support, and the practical takeaway.
T-cell maturation
Mixed research context, Intraperitoneal
T-cell maturation
Mixed research context, Intraperitoneal
Age-related immune inflammation
Intraperitoneal
Age-related immune inflammation
Intraperitoneal
This is a preclinical immune-aging signal with a distinct treatment setting; it does not establish healthier aging or cancer treatment in people.[32]
Evidence snapshot
Overall confidence
Zinc-dependent thymulin biology is better established than therapeutic use. Clinical effects remain preparation-specific and uncertain.[1][5][3]
Overall confidence is a page-level composite, not an average; it weighs evidence quality, route/molecule match, and practical limitations.
Human evidence
Human treatment evidence remains limited; endogenous thymulin activity also depends on zinc status.[6][5][3]
Animal / preclinical
Structural studies characterize its zinc-dependent conformation and support a role in thymic peptide signaling.[1][2][3][4]
Mechanism support
Zinc-bound thymulin contributes to T-cell maturation and communication between the thymus and hormone-producing organs. Its activity depends on both the peptide and zinc being present.[1]
Forms & administration
Experimental thymulin forms include intravenous synthetic FTS and zinc-bound injections, with animal-only formulations kept separate. Gene-based delivery produces the peptide within tissues. Zinc binding and delivery method influence activity and exposure.[1][5][3][36]
Dosing & protocols
These ranges are general reference points, not personal dosing instructions.
Typical Range
A current standalone human zinc-thymulin dose range is not established; historical FTS and related-variant doses describe different preparations.[5][7][1]
Frequency
Historical FTS reports and animal thymulin experiments use different frequencies; no repeat schedule is established for a current human product.[5][36]
Timing Considerations
A meal, exercise or bedtime anchor is not established for administered human zinc-thymulin.[1][5]
Cycle Length
A complete current-product human course is not established. Zinc-supplementation courses describe zinc exposure, rather than thymulin administration.[3][6]
Safety profile
Historical FTS reports and zinc-biomarker studies do not establish safety for a current zinc-thymulin product. The active zinc-bound complex, unbound FTS and gene-transfer preparations are different exposures.[1][5][3]
Regulatory status
United States
Thymulin is not an FDA-approved drug name. Availability of a supplement or research preparation does not establish approval for a medical use.[42]
International
Medicinal-product authorization outside the United States remains unconfirmed for the named preparation; status depends on the exact product and country.[42]
Sports & competition
WADA S0 prohibits pharmacological substances without governmental approval for human therapeutic use when no later section addresses them. An unapproved peptide preparation is not athlete-cleared.
How it works
Zinc-bound thymulin contributes to T-cell maturation and communication between the thymus and hormone-producing organs. Its activity depends on both the peptide and zinc being present.[1]
It may also influence inflammatory signaling and pain responses. The body’s own thymulin activity and the effects of an administered preparation are distinct.[36][3]
Research gaps & open questions
What the current literature has not yet settled about Thymulin:
A defined zinc-thymulin preparation needs controlled human studies measuring infection burden or immune function, rather than inferring treatment effects from circulating hormone measurements.[1][3]
Studies need to measure how long the active zinc-bound form remains available after administration and which doses are tolerable; historical FTS reports do not resolve those product questions.[5][2]
Animal inflammatory-pain and immune-aging findings need independent replication and human outcome trials before they can establish pain relief or healthier aging in people.[36][32]
Common questions
Does a zinc study prove thymulin treatment works?
History & discovery
Thymulin was identified as a thymic signal in the early 1970s. Subsequent work distinguished the nine-amino-acid factor from the zinc-bound active complex and examined its links with the endocrine system.[1]
Small human reports administered synthetic FTS in immune deficiency or cancer and measured immune responses. These preparations and incomplete courses do not establish a present-day zinc-thymulin product.[6][5]
Nuclear magnetic resonance experiments examined the peptide’s conformation. This strengthened molecular understanding without supplying evidence for a general clinical treatment.[2]
44 citations
Thymulin research centers on zinc-dependent immune signaling and communication between the thymus and endocrine system. Therapeutic evidence remains preliminary, with important differences between the native hormone and related preparations.[1][5][7][3][35][9][16][17][22][34][32][36]
